These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 10781886)

  • 1. Tissue distribution of 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione (NTBC) and its effect on enzymes involved in tyrosine catabolism in the mouse.
    Lock EA; Gaskin P; Ellis MK; McLean Provan W; Robinson M; Smith LL
    Toxicology; 2000 Apr; 144(1-3):179-87. PubMed ID: 10781886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tissue distribution of 2-(2-nitro-4-trifluoromethylbenzoyl)cyclohexane-1-3-dione (NTBC): effect on enzymes involved in tyrosine catabolism and relevance to ocular toxicity in the rat.
    Lock EA; Gaskin P; Ellis MK; Provan WM; Robinson M; Smith LL; Prisbylla MP; Mutter LC
    Toxicol Appl Pharmacol; 1996 Dec; 141(2):439-47. PubMed ID: 8975769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of NTBC (2-(2-nitro-4-fluoromethylbenzoyl)-1,3-cyclohexanedione) and mesotrione, inhibitors of 4-hydroxyphenyl pyruvate dioxygenase (HPPD) following a single dose to healthy male volunteers.
    Hall MG; Wilks MF; Provan WM; Eksborg S; Lumholtz B
    Br J Clin Pharmacol; 2001 Aug; 52(2):169-77. PubMed ID: 11488774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of 4-hydroxyphenylpyruvate dioxygenase by 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione and 2-(2-chloro-4-methanesulfonylbenzoyl)-cyclohexane-1,3-dione.
    Ellis MK; Whitfield AC; Gowans LA; Auton TR; Provan WM; Lock EA; Smith LL
    Toxicol Appl Pharmacol; 1995 Jul; 133(1):12-9. PubMed ID: 7597701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tyrosinemia produced by 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione (NTBC) in experimental animals and its relationship to corneal injury.
    Lock EA; Gaskin P; Ellis M; Provan WM; Smith LL
    Toxicol Appl Pharmacol; 2006 Aug; 215(1):9-16. PubMed ID: 16580702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of a low-protein diet and dietary supplementation of threonine on tyrosine and 2-(2-nitro-4-trifluoromethylbenzoyl) cyclohexane-1,3-dione-induced corneal lesions, the extent of tyrosinemia, and the activity of enzymes involved in tyrosine catabolism in the rat.
    Lock EA; Gaskin P; Ellis MK; Robinson M; Provan WM; Smith LL
    Toxicol Appl Pharmacol; 1998 May; 150(1):125-32. PubMed ID: 9630461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction of (4-hydroxyphenyl)pyruvate dioxygenase with the specific inhibitor 2-[2-nitro-4-(trifluoromethyl)benzoyl]-1,3-cyclohexanedione.
    Kavana M; Moran GR
    Biochemistry; 2003 Sep; 42(34):10238-45. PubMed ID: 12939152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From toxicological problem to therapeutic use: the discovery of the mode of action of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), its toxicology and development as a drug.
    Lock EA; Ellis MK; Gaskin P; Robinson M; Auton TR; Provan WM; Smith LL; Prisbylla MP; Mutter LC; Lee DL
    J Inherit Metab Dis; 1998 Aug; 21(5):498-506. PubMed ID: 9728330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From Weed Killer to Wonder Drug.
    Lock EA
    Adv Exp Med Biol; 2017; 959():175-185. PubMed ID: 28755195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting tyrosinaemia: a mathematical model of 4-hydroxyphenylpyruvate dioxygenase inhibition by nitisinone in rats.
    Ward JP; Dunster JL; Derks G; Mistry P; Salazar JD
    Math Med Biol; 2017 Sep; 34(3):335-390. PubMed ID: 27305933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tyrosinemia I, a model for human diseases mediated by 2-oxoacid-utilizing dioxygenases: hepatotoxin suppression by NTBC does not normalize hepatic collagen metabolism.
    Hanauske-Abel HM; Popowicz A; Remotti H; Newfield RS; Levy J
    J Pediatr Gastroenterol Nutr; 2002 Jul; 35(1):73-8. PubMed ID: 12142814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tyrosinaemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione).
    Holme E; Lindstedt S
    J Inherit Metab Dis; 1998 Aug; 21(5):507-17. PubMed ID: 9728331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel therapeutic trial of homogentisic aciduria in a murine model of alkaptonuria.
    Suzuki Y; Oda K; Yoshikawa Y; Maeda Y; Suzuki T
    J Hum Genet; 1999; 44(2):79-84. PubMed ID: 10083729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. D-serine-induced nephrotoxicity: possible interaction with tyrosine metabolism.
    Williams RE; Lock EA
    Toxicology; 2004 Sep; 201(1-3):231-8. PubMed ID: 15297036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydrophobicity-oriented drug design (HODD) of new human 4-hydroxyphenylpyruvate dioxygenase inhibitors.
    Ndikuryayo F; Kang WM; Wu FX; Yang WC; Yang GF
    Eur J Med Chem; 2019 Mar; 166():22-31. PubMed ID: 30684868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kidneys of mice with hereditary tyrosinemia type I are extremely sensitive to cytotoxicity.
    Jacobs SM; van Beurden DH; Klomp LW; Berger R; van den Berg IE
    Pediatr Res; 2006 Mar; 59(3):365-70. PubMed ID: 16492973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and bioevaluation of pyrazole-benzimidazolone hybrids as novel human 4-Hydroxyphenylpyruvate dioxygenase inhibitors.
    Xu YL; Lin HY; Ruan X; Yang SG; Hao GF; Yang WC; Yang GF
    Eur J Med Chem; 2015 Mar; 92():427-38. PubMed ID: 25590863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of nitisinone in tyrosine pathway disorders.
    Lock E; Ranganath LR; Timmis O
    Curr Rheumatol Rep; 2014 Nov; 16(11):457. PubMed ID: 25266991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological rescue of the 14CoS/14CoS mouse: hepatocyte apoptosis is likely caused by endogenous oxidative stress.
    Dieter MZ; Freshwater SL; Miller ML; Shertzer HG; Dalton TP; Nebert DW
    Free Radic Biol Med; 2003 Aug; 35(4):351-67. PubMed ID: 12899938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Product analysis and inhibition studies of a causative Asn to Ser variant of 4-hydroxyphenylpyruvate dioxygenase suggest a simple route to the treatment of Hawkinsinuria.
    Brownlee JM; Heinz B; Bates J; Moran GR
    Biochemistry; 2010 Aug; 49(33):7218-26. PubMed ID: 20677779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.